Teva Pharmaceutical Industries Limited American Depositary Shares
TEVADividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 12, 2017 | $0.09 | 2017-11-27 | 2017-11-28 |
| September 14, 2017 | $0.09 | 2017-08-25 | 2017-08-29 |
| June 22, 2017 | $0.34 | 2017-06-01 | 2017-06-05 |
| March 20, 2017 | $0.34 | 2017-02-28 | 2017-03-02 |
| December 20, 2016 | $0.34 | 2016-12-01 | 2016-12-05 |
Dividends Summary
- Consistent Payer: Teva Pharmaceutical Industries Limited American Depositary Shares has rewarded shareholders with 58 dividend payments over the past 14 years.
- Total Returned Value: Investors who held TEVA shares during this period received a total of $11.37 per share in dividend income.
- Latest Payout: The most recent dividend of $0.09/share was paid 3140 days ago, on December 12, 2017.
- Yield & Schedule: TEVA currently pays dividends quarterly with an annual yield of 2.65%.
- Dividend Growth: Since 2003, the dividend payout has grown by 15.5%, from $0.07 to $0.09.
Company News
Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors d...
Eli Lilly and Teva Pharmaceutical represent two different pharmaceutical strategies: Eli Lilly dominates the high-growth GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, posting 44% revenue growth and trading at a 33x forward P/E. Teva operates in generics and biosimilars with lower valuations (16.4x forward P/E) but faces declinin...
Teva Pharmaceutical Industries Ltd. announced the availability of its Q2 2026 Aide Memoire document to assist investors ahead of second quarter 2026 results, scheduled for release on July 29, 2026. The company also announced an upcoming conference call to discuss financial results. The article includes standard forward-looking statements and risk...
Teva Pharmaceutical has submitted a New Drug Application (NDA) to the FDA for ecopipam, a first-in-class dopamine D1 receptor antagonist for treating pediatric Tourette syndrome. The submission is supported by positive Phase 3 data published in JAMA Neurology, showing ecopipam significantly delayed time to relapse compared to placebo with a p-val...
UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 5,222 shares for approximately $143,000 on June 8, 2026, reducing his holdings by 3.60%. While his remaining stake of 139,763 shares keeps his interests aligned with investors, the sale follows a pattern of regular dispositions over the past year. The company faces headwinds from an upcom...
